We appreciate his thoughtful consideration of this critical issue.ChristopherReeve.

chronic sclerosis

1 billion out of a CNS
market value of $34. With the approval of new products and takeover
of markets for obsolete symptomatic therapies, the neuroprotection
market value will rise $11.

epilepsy muscular

Pharmaceutical Writers/Business Editors/Health/Medical
Writers/Biotech Writers/Health Editors/Medical Editors

DUBLIN, Ireland----Research and
Markets (http://www . By that
time neuroprotection will be an established part of the neurological
practice and measures will be available to achieve this effectively.

spinal migraine

hydrocephalus jakob

For more information, please call (800) 225-0292 or visit
http://www. Diseases covered include
cerebrovascular disorders, traumatic brain injury, spinal cord injury,
Alzheimer's disease, Parkinson's disease, Huntington's disease,
amyotrophic lateral sclerosis, multiple sclerosis, epilepsy and
ischemic optic neuropathy as well as retinal degeneration.

muscular diseases

The Foundation also vigorously
works to improve the quality of life for people living with disabilities
through its grants program, paralysis resource center, and advocacy efforts.

muscular chronic

Some of the products in
development at academic institutions that do not have a commercial
sponsor are also included.

An organized network of people with something in common who give and receive help , advice, friendship and emotional support.

bifida disorders

WASHINGTON, "On behalf of the Christopher Reeve
Foundation and the millions of people living with paralysis, we applaud
Senator Frist for his support of the Stem Cell Research Enhancement Act.5 billion by the year 2010 when it will
constitute a major and important component of the CNS market.

epilepsy jakob

researchandmarkets.

spinal spina

Research and Markets: With Approval Of New Products And Takeover Of Markets For Obsolete Symptomatic Therapies Neuroprotection Market Value Will Rise $11.5 Bi

headaches chronic

The report contains a profile of 109 companies that have a
neuroprotective product or products.

parkinson palsy

Stem
cells have the potential to cure diseases and conditions ranging from spinal
cord injury, Parkinson's disease and multiple sclerosis, to diabetes and heart
disease.

congenital spina

Senator Frist 's announcement brings us one step closer to expanding federal
funding of embryonic stem cell research and harnessing the power of government
to find better treatments and cures for millions of Americans . We are proud
of the role Christopher Reeve and the Foundation have played in advancing this
legislation and we look to Senator Frist's leadership to quickly pass the Stem
Cell Research Enhancement Act in the United States Senate this fall.

diseases migraine

com/reports/c1364) has
announced the addition of Neuroprotection - Drugs, Markets and
Companies to their offering
This report describes the role of neuroprotection in acute
disorders such as stroke and injuries of the nervous system as well as
in chronic diseases such as neurodegenerative disorders because many
of the underlying mechanisms of damage to neural tissues are similar
in all these conditions and several products are used in more than one
disorder .

diseases sclerosis

creutzfeldt neuralgias

"

About CRF
The Christopher Reeve Foundation (CRF) is committed to funding research
that develops treatments and cures for paralysis caused by spinal cord injury
and other central nervous system disorders. Although
anesthetics such as propofol are neuroprotective as well,
neuroprotection during surgery and anesthesia is discussed with the
aim of preventing and treating complications that result in CNS
damage.

bifida palsy

Pathomechanisms of diseases are described with steps at which
neuroprotective therapies are directed. Although an up-to-date search of the
literature was performed and selected 500 references are included, a
considerable amount of information has not been published anywhere
else.

congenital epilepsy

Some of the agents
are old established pharmaceuticals whereas others are new
biotechnology products.

fatigue bifida

Some of these
products are approved for other indications but are known to have a
neuroprotective effect.

diseases demyelinating

org.researchandmarkets.
For more information visit
http://www.

jakob diseases

com/reports/c1364

palsy migraine

Statement from Michael Manganiello Senior Vice President of Government Relations Christopher Reeve Foundation

Market analysis shows that products currently used that have a
neuroprotective effect have a market value of 5.

bifida parkinson

Over 300 products have been investigated for neuroprotective
effects including those from the categories of free radical
scavengers, anti-excitotoxic agents, apoptosis (programmed cell death)
inhibitors, anti-inflammatory agents, neurotrophic factors, metal ion
chelators , ion channel modulators and gene therapy.6 billion in all these areas.

demyelinating spinal

Clinical trials of various neuroprotective agents are described
and failures of trials in stroke and head injury are analyzed with
suggestions for improving the selection of drugs and design of trials.
The report is supplemented with 59 tables and 8 figures.